The insulin pump market is expected to grow to $5.1bn by 2023, driven by the increasing incidence of diabetes and adoption of next-generation hybrid closed-loop systems, which allow patients and health-care providers to better manage care. This first part of a two-part series highlights the rising competitive landscape of the four major players, Medtronic, Insulet, Tandem Diabetes Care and Valeritas, with insights from endocrinologists. The second part will look at the smaller players, which are gearing up to introduce new products in 2020.

With a growing number of diabetes apps on the market, patients and physicians can obtain a large amount of data to help manage the disease. In this second part of a two-part series on the blood glucose monitoring devices market, two endocrinologists express their views on the considerations and pitfalls of using apps to help manage diabetes, and they recommend specific apps.

Harbinger Health has raised a total of $190m since its founding in 2021. Its CEO Stephen Hahn told Medtech Insight in March that the company plans to develop a blood-based cancer test that is affordable, accessible and also more accurate than currently available tests.